High-dose radiation therapy for advanced pancreatic cancer after chemotherapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of high-dose radiation therapy in patients with locally advanced pancreatic cancer who have shown a positive response to initial chemotherapy. Participants will receive high-dose radiation treatment and may undergo an optional tumor biopsy, complete quality of life questionnaires, and donate blood samples for research. The study seeks to determine if this approach can improve treatment outcomes, enhance quality of life, or increase overall survival rates.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a histological or cytological diagnosis of LAPC.
* Have pancreatic tumour \<8.0 cm in greatest axial dimension at the time of treatment planning but final determination of eligibility will be based upon satisfying the radiation normal tissue constraints.
* Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (Karnofsky ≥70%).
* Life expectancy of greater than 6 months, as judged by the investigator.
* Patients must have had prior first-line chemotherapy for this cancer for at least 16 weeks without clinical or radiographic progression. There should be a washout of at least 2 weeks from first-line chemotherapy and start of therapy on clinical trial.
* Ability to understand and willing to sign a written informed consent document.
* Women must not be pregnant or breast-feeding. All females of child bearing potential must have a serum or urine pregnancy test to rule out pregnancy within 4 weeks prior to registration. All breastfeeding women should discontinue breastfeeding prior to study registration.

Exclusion Criteria:

* Metastatic disease at the time of registration
* Age\<18.
* Patients who have had prior systemic treatment (chemotherapy or any other anti-cancer agent) in the metastatic setting.
* Prior radiotherapy to the upper abdomen region that would result in overlap of RT volume for the current study.
* Patients who are currently on anti-cancer treatment including chemotherapy.
* Uncontrolled inter-current illness including, but not limited to: ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Pregnant and breastfeeding women.
* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
* Individuals with a history of a different malignancy except if they have been disease-free for at least 2 years and are deemed by the investigator to be at low risk for recurrence. Individuals with the following cancers are eligible if diagnosed and treated within the past 5 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin.
* Individuals with diseases precluding high dose ablative RT (e.g. scleroderma, gastric or bowel ulceration or perforation within the planned irradiated volume)
* Patient should NOT be treated with MR-Linac if they have any contraindications for MRI, including presence of a heart pacemaker, (ferrous) metallic foreign bodies, and severe claustrophobia. Patients will be screened and excluded from the study if they have previous anaphylactic reactions to gadolinium and severe kidney disease (glomerular filtration rate \< 30mL/min/1.73m2) or acute kidney disease.

Where it's running

• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting
• McGill University Health Centre
  Montreal, Quebec, Canada Recruiting

Study contacts

• Principal investigator: Erica Tsang, MD — University Health Network, Toronto
• Study coordinator: Anna Dodd
• Email: Anna.Dodd@uhn.ca
• Phone: 647-539-6498

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• AB801 with chemotherapy and immunotherapy for cholangiocarcinoma and pancreatic cancer

  This phase 1 study tests whether AB801 can be given safely with chemotherapy and immunotherapy in adults with border-line resectable, locally advanced, or metastatic cholangiocarcinoma or pancreatic cancer.

  Recruiting Phase 1 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT07619313

• Surgery after tumor-shrinking treatment for locally advanced pancreatic cancer

  This project will test whether doing surgery after at least four months of chemotherapy helps people with locally advanced pancreatic cancer that was initially considered not removable live longer and feel better.

  Recruiting Azienda Ospedaliera di Padova · Padova · NCT07241663

• XER-001 (nasoduodenal amifostine) with SBRT for locally advanced pancreatic cancer

  This trial tests whether giving XER-001 through a nasoduodenal tube together with stereotactic body radiotherapy (SBRT) is safe and helpful for people with locally advanced pancreatic cancer.

  Recruiting at 5 sites Phase 1/2 Xerient Pharma · Duarte, California and 4 other locations · NCT07157033

• Comparing NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen for advanced pancreatic adenocarcinoma

  This compares NALIRIFOX to a modified gemcitabine/nab‑paclitaxel/cisplatin regimen to see if it helps people with untreated locally advanced or metastatic pancreatic ductal adenocarcinoma live longer or have better tumor responses.

  Recruiting at 2 sites Phase 2 Medical University of South Carolina · Charleston, South Carolina and 1 other locations · NCT07076212

• Adding panitumumab to chemotherapy for unresectable or metastatic KRAS wild-type pancreatic cancer

  This trial will test whether giving the antibody panitumumab along with standard chemotherapy helps people with unresectable, locally advanced, or metastatic KRAS wild-type pancreatic cancer live longer.

  Recruiting at 272 sites Phase 3 SWOG Cancer Research Network · Anchorage, Alaska and 273 other locations · NCT06998940

• Cell-based gene therapy for advanced pancreatic cancer after chemotherapy

  This study is testing a new cell-based gene therapy called RR001 to see if it can help people with advanced pancreatic cancer feel better after chemotherapy and possibly make them eligible for surgery.

  Recruiting Phase 1/2 EIR Biotherapies s.r.l. · Modena, Italy · NCT06861452

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.